Prolapse device makers FEMSelect secures new funding and announces move to US
Half of women over 50 experience prolapse
FEMSelect, a privately held medical device company focused on pelvic organ prolapse (POP), has announced a successful oversubscribed equity financing round. The company says the funding will support leadership expansion, commercial growth, and a relocation of its headquarters to the United States.
The round was led by existing investors New Age Ventures and Triventures, with continued support from Robin Hood Ventures and RAD Biomed. New backers include Nordwand Capital, Avea Ventures, and Terra Verde Comp, signalling continued investor confidence in FEMSelect’s trajectory. The amount invested during this round was undisclosed.
"With participation from long-time and new investors, this influx of capital marks a major leap forward in our mission to redefine care for millions of underserved women worldwide," said Renee Selman, Executive Chairwoman of the Board.
"With a strengthened leadership team, expanded financial firepower, and a powerful product pipeline, FEMSelect is poised to accelerate growth and lead the way in transformative women's health solutions."
Minimally invasive support for prolapse
Pelvic Organ Prolapse (POP) is a condition that affects nearly half of women over the age of 50. It occurs when the connective tissue and muscles of the pelvic floor can’t support the pelvic organs and can result in the dropping of the uterus and cervix from their normal position. The resulting pressure and bulging may affect exercise, intimacy, even going to the bathroom.
For many, a pessary, physical therapy, and Kegels aren’t enough. FEMSelect’s EnPlace system offers a minimally invasive option that can be fitted in a procedure taking just 30 minutes. An ‘anchor unit’ is introduced through the vaginal wall and is secure to the pelvic floor ligament to provide stabilization.
The company says the approach avoids many of the complications and extended recovery times associated with conventional surgical methods.
Move to the United States, leadership changes and expansion plans
The company, originally based in Israel, will now relocate its global headquarters to the U.S. as it looks to increase its presence in its largest market and pursue further strategic partnerships.
As part of its scaling efforts, FEMSelect has named Sasha Schrode as its new Chief Executive. Schrode, formerly of Serpex Medical, where she led the company through a successful acquisition, brings a background in healthcare innovation and commercial development.
"FEMSelect has the power to transform women's healthcare, and I'm thrilled to help bring this breakthrough to millions worldwide," said Schrode.
"Unlike traditional surgery—which often involves extensive dissection, longer recovery, and higher risk—the EnPlace procedure is minimally invasive, requires no dissection, and allows most women to go home the same day and resume their lives quickly."
Debbie Garner has been appointed as President, tasked with leading FEMSelect’s U.S. and international expansion. The firm is also strengthening its governance with the appointment of Rakesh Tailor, CEO of Contura International, to the Board of Directors. Tailor previously oversaw the development of Bulkamid and its acquisition by Axonics in 2021.